These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 13727136)

  • 1. Complement-fixation tests for antisera prepared against epithelial and fibroblast cell strains.
    MUSTAKALLIO E; GRONROOS JA
    Ann Med Exp Biol Fenn; 1961; 39():143-6. PubMed ID: 13727136
    [No Abstract]   [Full Text] [Related]  

  • 2. Complement-fixation tests for antisera prepared against strain HeLa cell and 5 cell strains derived from human breast carcinoma.
    MUSTAKALLIO E; GRONROOS JA
    Ann Med Exp Biol Fenn; 1957; 35(Suppl 12):1-9. PubMed ID: 13498468
    [No Abstract]   [Full Text] [Related]  

  • 3. CYTOTOXIC EFFECTS OF COMPLEMENT AND IMMUNE SERA PREPARED AGAINST EPITHELIAL- AND FIBROBLAST-LIKE CELL STRAINS.
    GROENROOS JA; MUSTAKALLIO E
    Ann Med Exp Biol Fenn; 1963; 41():399-406. PubMed ID: 14085825
    [No Abstract]   [Full Text] [Related]  

  • 4. [Detection of antibodies in complement fixation reaction in rabbits immunized by various vaccines from Brown-Pearce carcinoma].
    GARDASH'IAN AM; RADZIKHOVSKAIA RM
    Vopr Onkol; 1958; 4(6):655-9. PubMed ID: 13636113
    [No Abstract]   [Full Text] [Related]  

  • 5. [Serological reaction used in the physiopathological study of neoplasms. VI. Isolation of the serologically-active fraction].
    Marzona M; Dovis M; Chiesa D; Molfese G; Biarese V; Lovisetto P
    Boll Soc Ital Biol Sper; 1977 May; 53(9):706-9. PubMed ID: 911520
    [No Abstract]   [Full Text] [Related]  

  • 6. [Complement fixation reaction with human blood coagulum extract investigated with the aid of the blood serum of cancer patients].
    RAVKINA LI
    Vopr Onkol; 1960; 6(11)():70-4. PubMed ID: 13739917
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prolonged heterologous transplantation of mouse tumor to rats. II. Complement fixation reaction in the study of antigenic properties of Ehrlich ascites carcinoma in heterotransplantation].
    PODOPLELOV II
    Biull Eksp Biol Med; 1959 Jan; 47(1):52-6. PubMed ID: 13638288
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparative studies on the antigenic structure of tumor and homologous normal tissues. I. Studies on antigenic properties of Gueren's carcinoma and of normal rat uterus using complement fixation reaction].
    LOMAKIN MS
    Biull Eksp Biol Med; 1959 May; 47(5):91-5. PubMed ID: 13671048
    [No Abstract]   [Full Text] [Related]  

  • 9. Complement as effector system in cancer immunotherapy.
    Macor P; Tedesco F
    Immunol Lett; 2007 Jul; 111(1):6-13. PubMed ID: 17572509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibody and complement functions in cancer].
    DITTMAR F
    Hippokrates; 1958 Jul; 29(13):403-5. PubMed ID: 13574701
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of capsule in serotypic differences and complement fixation by Lactococcus garvieae.
    Barnes AC; Ellis AE
    Fish Shellfish Immunol; 2004 Feb; 16(2):207-14. PubMed ID: 15123324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement function in mAb-mediated cancer immunotherapy.
    Gelderman KA; Tomlinson S; Ross GD; Gorter A
    Trends Immunol; 2004 Mar; 25(3):158-64. PubMed ID: 15036044
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer exploiting complement: a clue or an exception?
    Loveland BE; Cebon J
    Nat Immunol; 2008 Nov; 9(11):1205-6. PubMed ID: 18936777
    [No Abstract]   [Full Text] [Related]  

  • 14. Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines.
    Moghimi SM; Andresen TL
    Mol Immunol; 2009 May; 46(8-9):1571-2. PubMed ID: 19286261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development.
    Gancz D; Fishelson Z
    Mol Immunol; 2009 Sep; 46(14):2794-800. PubMed ID: 19501402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity.
    Welsch JA; Moe GR; Rossi R; Adu-Bobie J; Rappuoli R; Granoff DM
    J Infect Dis; 2003 Dec; 188(11):1730-40. PubMed ID: 14639545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serologic activities of serum fractions in animal neoplasia.
    LIPPINCOTT SW; FONG CT; THORNTON H; ELLERBROOK LD; NUTTER J
    J Natl Cancer Inst; 1955 Apr; 15(5):1231-5. PubMed ID: 14368269
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparative studies on serological properties of anti-cancer horse serum fractions].
    NAZARENKO NA; GOSTEV VS
    Biull Eksp Biol Med; 1959 Mar; 47(3):70-5. PubMed ID: 13651284
    [No Abstract]   [Full Text] [Related]  

  • 19. Cord factor as antigen in complement fixation and flocculation tests.
    TOMMILA V; HONKAPOHJA H
    Ann Med Exp Biol Fenn; 1954; 32(3):219-24. PubMed ID: 14377015
    [No Abstract]   [Full Text] [Related]  

  • 20. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
    Livingston PO; Hood C; Krug LM; Warren N; Kris MG; Brezicka T; Ragupathi G
    Cancer Immunol Immunother; 2005 Oct; 54(10):1018-25. PubMed ID: 15926079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.